Suvretta Capital Management Reports New 7.7% Passive Stake in Lexeo Therapeutics, Inc.

On April 13, 2026, Suvretta Capital Management, LLC, alongside Averill Master Fund, Ltd. and Aaron Cowen, filed a Schedule 13G disclosing a new significant stake in Lexeo Therapeutics, Inc. (LXEO). The filing indicates that Suvretta Capital Management and Aaron Cowen beneficially own 5,674,778 shares of common stock, representing a 7.7% ownership stake in the company. Of this total, Averill Master Fund, Ltd. directly holds 4,827,730 shares, or approximately 6.5% of the class. The event triggering this filing occurred on April 6, 2026. The reporting persons have shared voting and dispositive power over the reported shares. This passive investment filing includes a certification that the shares were not acquired for the purpose of changing or influencing the control of the issuer. Aaron Cowen is identified as the control person for Suvretta Capital Management, LLC. The shares are held by advisory clients of Suvretta, with Averill Master Fund being the only client exceeding a 5% interest individually.